Frontiers in Oncology / Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer : a case report and literature review

Autor: Piringer, Gudrun, Decker, Jörn, Trommet, Vera, Kühr, Thomas, Heibl, Sonja, Dörfler, Konrad, Thaler, Josef

Metastatic BRAF^V600E mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAF^V6

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3361::c156b587c8d8421cca8be1f786ed0eb1
https://epub.jku.at/doi/10.3389/fonc.2023.1166545

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

Autor: Wöll E; St. Vinzenz Krankenhaus Betriebs GmbH, Zams, Austria e.woell@krankenhaus-zams.at., Thaler J; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria., Keil F; 3rd Medical Department, Hanusch Hospital, Vienna, Austria., Gruenberger B; St. John of God's Hospital, Vienna, Austria., Hejna M; Medical University of Vienna, Vienna, Austria., Eisterer W; Medical University Hospital Innsbruck, Innsbruck, Austria., Fridrik MA; Kepler Universitätsklinikum GmbH, Med Campus III, Klinik für Interne, Linz, Austria., Ulmer H; Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, Austria., Trommet V; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria., Huemer F; IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria., Weiss L; IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria., Greil R; IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria.

Publikováno v: Anticancer research [Anticancer Res] 2017 Oct; Vol. 37 (10), pp. 5553-5558.